Komori
General Meetings of Shareholders4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of Convocation of the 11th Annual General Meeting of Shareholders

The details of the 11th Annual General Meeting of Shareholders and the proposals to be submitted for approval were announced. Approval is being sought for a reduction in capital and disposition of other capital surplus, the election of directors, the appointment of an accounting auditor, and the issuance of stock options and restricted stock-based compensation.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
567576
Thousands of yen (amount by which capital will decrease)
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (11th fiscal year)
2026
Apr 24
Date and time(Friday) (受付開始: 1:30 p.m.)21 days from this disclosure to the meeting
Matters for resolution5 items
  1. Reduction in the Amount of Capital and Disposition of Other Capital Surplus

  2. Election of 1 Director (excluding Directors who are Audit & Supervisory Committee Members)

  3. Appointment of Accounting Auditor

  4. Delegation to the Board of Directors of the Authority to Determine the Offering Terms for Share Acquisition Rights Issued as Stock Options

  5. Determination of Compensation under the Restricted Stock-Based Compensation Plan for Directors (excluding Directors who are Audit and Supervisory Committee Members)

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
1Nominees
0New
0Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (11th fiscal year)
Date and time2:00 p.m. on 24 April 2026 (Friday) (受付開始: 1:30 p.m.)
Matters for resolutionProposal 1: Reduction in the Amount of Capital and Disposition of Other Capital Surplus, Proposal No. 2: Election of 1 Director (excluding Directors who are Audit & Supervisory Committee Members), Proposal No. 3: Appointment of Accounting Auditor, Proposal 4: Delegation to the Board of Directors of the Authority to Determine the Offering Terms for Share Acquisition Rights Issued as Stock Options, Proposal 5: Determination of Compensation under the Restricted Stock-Based Compensation Plan for Directors (excluding Directors who are Audit and Supervisory Committee Members)
Shareholder ProposalNo
Director nominee1, including 0 new and 0 outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reduction in capital and disposition of other capital surplus are intended to cover the deficit and secure flexibility and agility in future capital policies. The stock options are intended to increase motivation and morale toward improving performance and enhancing corporate value. The restricted stock-based compensation is intended to provide incentives for the sustained enhancement of corporate value and promote the sharing of value with shareholders. The change in accounting auditor was made because, after comprehensively considering the firm's size, quality control, professional ethics, independence, audit structure and audit fees, the new audit firm was deemed suitable.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 11th Annual General Meeting of Shareholders | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori